Want to see SG:1B1 full AI Analyst Report?
1B1 Stock Chart & Stats
S$0.36
S$0.00(0.00%)
At close: 4:00 PM EST
S$0.36
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.33 - S$0.40
Previous CloseN/A
Volume0.00
Average Volume (3M)50.29K
Market Cap
S$50.76M
Enterprise ValueS$52.57
Total Cash (Recent Filing)S$6.96M
Total Debt (Recent Filing)S$2.40M
Price to Earnings (P/E)5.8
Beta0.20
Next Earnings
Jan 14, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.12%
Share Statistics
EPS (TTM)0.07
Shares Outstanding156,309,900
10 Day Avg. Volume16,820
30 Day Avg. Volume50,290
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.79
Price to Sales (P/S)3.01
P/FCF Ratio7.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained gross margins in the mid-80s and a ~44% net margin imply durable pricing power and a capital-light, high-margin business model. This supports stable internal funding for R&D/dividends and preserves resilience across industry cycles over the next several months.
Consistent Free Cash FlowFCF tracking nearly 0.9–1.0x net income across multiple years demonstrates high earnings quality and reliable cash generation. That consistency enables reinvestment, steady shareholder returns, and provides a buffer against earnings volatility over a 2–6 month horizon.
De-risked Balance SheetMaterial improvement in leverage and rising equity indicate reduced financial risk and greater flexibility to allocate capital or withstand downturns. A conservative balance sheet supports strategic decisions and durable operations without near-term refinancing pressure.
Bears Say
Revenue And Earnings VolatilityIrregular top-line and profit swings reduce forecasting reliability and make capital allocation harder. For a small specialist, recurring volatility can threaten consistent investment, hiring, or dividend plans and raises execution risk over the coming months.
Incomplete 2026 Capital Efficiency DataAssets rose in 2026 but detailed leverage and return ratios aren't provided, limiting assessment of recent capital efficiency. That opacity creates uncertainty about whether the de-risking trend persisted or if balance sheet mix shifted unfavorably.
Cash Coverage VariabilityPeriods where operating cash flow lagged net income indicate weaker cash conversion under stress. If such variability recurs it could constrain discretionary spending or dividends, reducing the firm’s margin for error in adverse quarters.
1B1 FAQ
What was HC Surgical Specialists Ltd’s price range in the past 12 months?
HC Surgical Specialists Ltd lowest share price was S$0.33 and its highest was S$0.40 in the past 12 months.
What is HC Surgical Specialists Ltd’s market cap?
HC Surgical Specialists Ltd’s market cap is S$50.76M.
When is HC Surgical Specialists Ltd’s upcoming earnings report date?
HC Surgical Specialists Ltd’s upcoming earnings report date is Jan 14, 2027 which is in 149 days.
How were HC Surgical Specialists Ltd’s earnings last quarter?
HC Surgical Specialists Ltd released its earnings results on Jul 30, 2026. The company reported S$0.02 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is HC Surgical Specialists Ltd overvalued?
According to Wall Street analysts HC Surgical Specialists Ltd’s price is currently Overvalued.
Does HC Surgical Specialists Ltd pay dividends?
HC Surgical Specialists Ltd pays a Notavailable dividend of S$0.009 which represents an annual dividend yield of 6.12%. See more information on HC Surgical Specialists Ltd dividends here
What is HC Surgical Specialists Ltd’s EPS estimate?
HC Surgical Specialists Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HC Surgical Specialists Ltd have?
HC Surgical Specialists Ltd has 156,309,900 shares outstanding.
What happened to HC Surgical Specialists Ltd’s price movement after its last earnings report?
HC Surgical Specialists Ltd reported an EPS of S$0.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of HC Surgical Specialists Ltd?
Currently, no hedge funds are holding shares in SG:1B1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HC Surgical Specialists Ltd
HC Surgical Specialists Limited, an investment holding company, primarily delivers a diverse spectrum of medical services across Singapore. Through its network of clinics, the company specializes in endoscopic procedures, such as gastroscopies and colonoscopies, in addition to providing general surgical services with a notable focus on colorectal issues. Their expertise further extends to treating a variety of conditions, including haemorrhoids, anal fissures, hernias, anal abscesses, cholecystitis, anal fistulas, appendicitis, colorectal and gastric cancers, lipomas, and cysts, utilizing advanced techniques like vein laser vascular therapy and laparoscopy. Moreover, the company offers extensive orthopedic services. These address concerns such as joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, tenosynovitis, tunnel syndrome, and various wounds or lumps. Surgical interventions include joint replacements, arthroscopic procedures, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, and fracture management, supported by orthobiologic injections. Beyond clinical care, the company provides comprehensive home care services, encompassing medical, nursing, physiotherapy, speech, occupational therapy, and ambulance support. Their community health initiatives include health screenings, management of acute and chronic conditions, pre-employment check-ups, and participation in public health schemes such as the 'swab and send home' program, the community health assist scheme, and COVID-19 testing. To support accurate diagnosis, a full array of diagnostic tests is available, including blood work, X-rays, ultrasounds, CT scans, and MRIs. The company was founded in Singapore in 2015, where it continues to be headquartered.
Technical Analysis
Hyphens Pharma International Ltd.
―
Medtecs International Corporation Ltd.
―
UG Healthcare Corp. Ltd.
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―








